Clinical Trial Update: 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing six cycles of FEC (5-fluorouracil, epirubicin, cyclophosphamide) versus three cycles of FEC followed by three cycles of docetaxel in h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-fluorouracil (5-FU) (5-fluorouracil)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Martin-Luther-Universität Halle-Wittenberg | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN